Landscape → Respiratory

Cystic Fibrosis

304 clinical trials

58 active

304 total (since 2015)

Phase 1 Active

91 total

Phase 2 Active

130 total

Phase 3 Active

80 total

Phase 4 Active

43 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

Vertex Pharmaceuticals Incorporated 10 63 5

Sionna Therapeutics Inc. 2 0 0

Boehringer Ingelheim 1 2 3

CSL Behring 1 1 0

Verona Pharma plc 1 1 0

Arcturus Therapeutics, Inc. 1 1 0

Krystal Biotech, Inc. 1 0 1

SpliSense Ltd. 1 1 0

Haisco Pharmaceutical Group Co., Ltd. 1 1 0

Anagram Therapeutics, Inc. 1 0 0

Roche 1 0 0

ReCode Therapeutics 1 0 0

Reistone Biopharma Company Limited 1 0 0

Respirion Pharmaceuticals Pty Ltd 1 0 0

4D Molecular Therapeutics 1 0 0

NCT06449677 RECRUITING

Bionic Pancreas in CFRD

Jaeb Center for Health Research n=150

NCT05844449 ENROLLING BY INVITATION

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Vertex Pharmaceuticals Incorporated n=174

NCT05331183 ACTIVE NOT RECRUITING

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Vertex Pharmaceuticals Incorporated n=297

NCT06149793 ACTIVE NOT RECRUITING

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

University of Minnesota n=8

NCT06996951 RECRUITING

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

Indiana University n=64

NCT07274020 NOT YET RECRUITING

Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients

Assiut University n=140

NCT05422222 RECRUITING

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Vertex Pharmaceuticals Incorporated n=210

NCT06460506 ACTIVE NOT RECRUITING

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Vertex Pharmaceuticals Incorporated n=50

NCT05444257 ACTIVE NOT RECRUITING

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Vertex Pharmaceuticals Incorporated n=822

NCT06810167 RECRUITING

Assessing Tenapanor as a Treatment of CF-related Constipation.

Massachusetts General Hospital n=25

NCT06739720 NOT YET RECRUITING

RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue

The University of Hong Kong n=130

NCT06660992 RECRUITING

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Haisco Pharmaceutical Group Co., Ltd. n=669

NCT06413368 NOT YET RECRUITING

Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study

Children's Hospital Los Angeles n=20

NCT05153317 COMPLETED

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Vertex Pharmaceuticals Incorporated n=71

NCT05788965 COMPLETED

Semaglutide in CFRD

University of Minnesota n=8

NCT04594369 COMPLETED

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Insmed Incorporated n=1,767

NCT02325362 COMPLETED

Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

Assistance Publique - Hôpitaux de Paris n=16

NCT05882357 COMPLETED

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Vertex Pharmaceuticals Incorporated n=70

NCT04969224 COMPLETED

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated n=82

NCT03525574 COMPLETED

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Vertex Pharmaceuticals Incorporated n=507

NCT05006573 TERMINATED

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

AstraZeneca n=100

NCT05408910 WITHDRAWN

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

Wake Forest University Health Sciences

NCT04183790 COMPLETED

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

Vertex Pharmaceuticals Incorporated n=64

NCT02496780 TERMINATED

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

University of Minnesota n=65

NCT03277196 COMPLETED

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Vertex Pharmaceuticals Incorporated n=86

NCT05033080 COMPLETED

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Vertex Pharmaceuticals Incorporated n=435

NCT04235140 COMPLETED

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Vertex Pharmaceuticals Incorporated n=52

NCT04039087 COMPLETED

Sildenafil Exercise: Role of PDE5 Inhibition

National Jewish Health n=26

NCT05274269 COMPLETED

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Vertex Pharmaceuticals Incorporated n=307

NCT03070522 COMPLETED

Prednisone in Cystic Fibrosis Pulmonary Exacerbations

The Hospital for Sick Children n=76

NCT05076149 COMPLETED

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Vertex Pharmaceuticals Incorporated n=597

NCT04545515 COMPLETED

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Vertex Pharmaceuticals Incorporated n=120

NCT03537651 COMPLETED

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Vertex Pharmaceuticals Incorporated n=130

NCT02950883 COMPLETED

Saline Hypertonic in Preschoolers + CT

University of Washington, the Collaborative Health Studies Coordinating Center n=116

NCT04058366 COMPLETED

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Vertex Pharmaceuticals Incorporated n=251

NCT03460704 TERMINATED

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

Zambon SpA n=287

NCT03093974 COMPLETED

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

Zambon SpA n=377

NCT02565914 COMPLETED

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated n=1,131

NCT02725567 COMPLETED

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Vertex Pharmaceuticals Incorporated n=57

NCT04599465 COMPLETED

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated n=69

NCT04362761 COMPLETED

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Vertex Pharmaceuticals Incorporated n=172

NCT05111145 COMPLETED

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated n=86

NCT04043806 COMPLETED

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Vertex Pharmaceuticals Incorporated n=458

NCT04537793 COMPLETED

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Vertex Pharmaceuticals Incorporated n=83

NCT02888730 TERMINATED

Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

Virginie ESCABASSE n=86

NCT03601637 COMPLETED

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Vertex Pharmaceuticals Incorporated n=61

NCT03181932 COMPLETED

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Savara Inc. n=188

NCT04353817 COMPLETED

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Vertex Pharmaceuticals Incorporated n=121

NCT03698448 WITHDRAWN

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

AlgiPharma AS

NCT03219164 TERMINATED

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Gilead Sciences n=149

NCT03447262 TERMINATED

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Vertex Pharmaceuticals Incorporated n=484

NCT03691779 COMPLETED

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Vertex Pharmaceuticals Incorporated n=71

NCT03066453 TERMINATED

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

University Hospital, Lille n=23

NCT04105972 COMPLETED

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Vertex Pharmaceuticals Incorporated n=176

NCT04058353 COMPLETED

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Vertex Pharmaceuticals Incorporated n=271

NCT02544451 COMPLETED

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Vertex Pharmaceuticals Incorporated n=246

NCT03125395 COMPLETED

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated n=57

NCT04468100 COMPLETED

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

AO GENERIUM n=100

NCT04411901 COMPLETED

The Role of Vitamin D3 in Pediatric Bronchiectasis Severity

Heba Omara n=40

NCT03525444 COMPLETED

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Vertex Pharmaceuticals Incorporated n=405

NCT02456103 TERMINATED

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

PTC Therapeutics n=246

NCT03447249 COMPLETED

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Vertex Pharmaceuticals Incorporated n=385

NCT02953314 COMPLETED

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated n=83

NCT03068312 COMPLETED

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Vertex Pharmaceuticals Incorporated n=38

NCT03559062 COMPLETED

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated n=67

NCT03633526 TERMINATED

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Vertex Pharmaceuticals Incorporated n=18

NCT03525548 COMPLETED

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Vertex Pharmaceuticals Incorporated n=113

NCT03460990 COMPLETED

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Vertex Pharmaceuticals Incorporated n=116

NCT03150719 COMPLETED

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated n=98

NCT02412111 COMPLETED

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Vertex Pharmaceuticals Incorporated n=156

NCT02742519 TERMINATED

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Vertex Pharmaceuticals Incorporated n=14

NCT02797132 COMPLETED

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Vertex Pharmaceuticals Incorporated n=62

NCT02279498 COMPLETED

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Anthera Pharmaceuticals n=128

NCT02934698 COMPLETED

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Medical University of South Carolina n=2

NCT02516410 COMPLETED

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated n=168

NCT02347657 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Vertex Pharmaceuticals Incorporated n=510

NCT02392234 COMPLETED

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Vertex Pharmaceuticals Incorporated n=248

NCT02734810 COMPLETED

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Anthera Pharmaceuticals n=15

NCT02390219 COMPLETED

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Vertex Pharmaceuticals Incorporated n=46

NCT02514473 COMPLETED

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated n=206

NCT07450547 NOT YET RECRUITING

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Anagram Therapeutics, Inc.

NCT06962852 ACTIVE NOT RECRUITING

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

Boehringer Ingelheim

NCT07108153 RECRUITING

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

Sionna Therapeutics Inc.

NCT02740868 RECRUITING

Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease

The Hospital for Sick Children

NCT05668741 RECRUITING

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Vertex Pharmaceuticals Incorporated

NCT06237335 RECRUITING

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

ReCode Therapeutics

NCT06016088 RECRUITING

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Respirion Pharmaceuticals Pty Ltd

NCT07289035 NOT YET RECRUITING

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

Azienda Ospedaliera Universitaria Integrata Verona

NCT05248230 RECRUITING

4D-710 in Adult Patients With Cystic Fibrosis

4D Molecular Therapeutics

NCT07048262 RECRUITING

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

CSL Behring

NCT06559150 RECRUITING

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Verona Pharma plc

NCT06366724 RECRUITING

LIFT: Life Improvement Trial

Brigham and Women's Hospital

NCT06747858 RECRUITING

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Arcturus Therapeutics, Inc.

NCT06998043 RECRUITING

Study With Phage for CF Subjects With Pseudomonas Lung Infection

BiomX Ltd

NCT06981091 NOT YET RECRUITING

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

S-INFINITY Pharmaceuticals Co., Ltd

NCT06364176 RECRUITING

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

University of Kansas Medical Center

NCT06952413 RECRUITING

Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

National Center of Neurology and Psychiatry, Japan

NCT04731272 RECRUITING

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

University of Pennsylvania

NCT03925194 RECRUITING

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF

Heidelberg University

NCT06211062 RECRUITING

The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Nova Southeastern University

NCT06429176 RECRUITING

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis

SpliSense Ltd.

NCT06526923 RECRUITING

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Spirovant Sciences, Inc.

NCT06663176 RECRUITING

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)

Thirty Respiratory Limited

NCT06515002 TERMINATED

A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

Boehringer Ingelheim

NCT03489629 COMPLETED

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

University of North Carolina, Chapel Hill

NCT03375047 COMPLETED

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

Sanofi

NCT05616221 COMPLETED

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Armata Pharmaceuticals, Inc.

NCT05453578 COMPLETED

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04375514 TERMINATED

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Arrowhead Pharmaceuticals

NCT02649751 TERMINATED

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

University Hospital, Brest

NCT06478706 COMPLETED

A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

Enterprise Therapeutics Ltd

NCT06468527 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

Kors van der Ent

NCT06159725 COMPLETED

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Clarametyx Biosciences, Inc.

NCT05865886 COMPLETED

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Boehringer Ingelheim

NCT03506061 COMPLETED

Trikafta in Cystic Fibrosis Patients

Emory University

NCT04530383 TERMINATED

Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes

University of Kansas Medical Center

NCT03617718 COMPLETED

Project 2 Airway Potential Hydrogen (pH) in Asthma

Case Western Reserve University

NCT05495243 COMPLETED

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Renovion, Inc.

NCT05010577 COMPLETED

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

BiomX, Inc.

NCT05239611 COMPLETED

Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis

University of Kansas Medical Center

NCT04884308 COMPLETED

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

Johns Hopkins University

NCT04322929 COMPLETED

Roflumilast in Non-CF Bronchiectasis Study (2019)

The University of Hong Kong

NCT03822455 TERMINATED

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

AlgiPharma AS

NCT03265288 COMPLETED

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Laurent Pharmaceuticals Inc.

NCT05601778 COMPLETED

A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis

Haisco Pharmaceutical Group Co., Ltd.

NCT05719311 COMPLETED

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

Entero Therapeutics

NCT04853368 TERMINATED

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

AbbVie

NCT02694393 TERMINATED

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

Schmidhofer, Mark, MD

NCT02919995 COMPLETED

A Study of RPL554 in Patients With Cystic Fibrosis

Verona Pharma plc

NCT05101915 TERMINATED

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Papworth Hospital NHS Foundation Trust

NCT03551691 COMPLETED

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

Children's Hospital of Philadelphia

NCT04596319 COMPLETED

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Armata Pharmaceuticals, Inc.

NCT04684641 COMPLETED

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

Yale University

NCT05090904 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Insmed Incorporated

NCT04126473 COMPLETED

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Eloxx Pharmaceuticals, Inc.

NCT05641298 WITHDRAWN

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Aceragen

NCT03969888 COMPLETED

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

AbbVie

NCT04006873 COMPLETED

Gut Imaging for Function & Transit in Cystic Fibrosis Study 2

Nottingham University Hospitals NHS Trust

NCT03912233 COMPLETED

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03218917 COMPLETED

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Insmed Incorporated

NCT03451045 COMPLETED

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Corbus Pharmaceuticals Inc.

NCT03597347 TERMINATED

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Savara Inc.

NCT04135495 COMPLETED

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Eloxx Pharmaceuticals, Inc.

NCT03625466 COMPLETED

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Vertex Pharmaceuticals Incorporated

NCT04375878 COMPLETED

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Entero Therapeutics

NCT03768089 COMPLETED

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03746483 COMPLETED

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Entero Therapeutics

NCT02323100 TERMINATED

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

National Jewish Health

NCT03911713 COMPLETED

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03227471 COMPLETED

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03748199 COMPLETED

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

Santhera Pharmaceuticals

NCT04302662 COMPLETED

Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs

AzurRx SAS

NCT02709109 COMPLETED

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Parion Sciences

NCT02343445 COMPLETED

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

Parion Sciences

NCT02508207 COMPLETED

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated

NCT03870841 TERMINATED

The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

Pulmocide Ltd

NCT03377556 COMPLETED

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

NCT04059094 TERMINATED

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Boehringer Ingelheim

NCT02444091 COMPLETED

Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

Haukeland University Hospital

NCT03224351 COMPLETED

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03000348 COMPLETED

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NovaBiotics Ltd.

NCT02498535 TERMINATED

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

Novoteris, LLC

NCT02730793 TERMINATED

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Virginia Commonwealth University

NCT02951195 COMPLETED

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT02566044 COMPLETED

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

Novartis Pharmaceuticals

NCT02955888 TERMINATED

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Liminal BioSciences Ltd.

NCT03206788 TERMINATED

Losartan and Inflammation in Cystic Fibrosis

University of Miami

NCT02951182 COMPLETED

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT02971839 TERMINATED

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Vertex Pharmaceuticals Incorporated

NCT02712983 COMPLETED

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Novartis Pharmaceuticals

NCT03251092 COMPLETED

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Proteostasis Therapeutics, Inc.

NCT03500263 COMPLETED

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Proteostasis Therapeutics, Inc.

NCT03591094 COMPLETED

Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

Proteostasis Therapeutics, Inc.

NCT03756922 SUSPENDED

A DDI Study of FDL169 and FDL176 in Healthy Subjects

Flatley Discovery Lab LLC

NCT03020719 COMPLETED

The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis

University of Minnesota

NCT03229252 COMPLETED

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Spyryx Biosciences, Inc.

NCT02730208 COMPLETED

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Vertex Pharmaceuticals Incorporated

NCT03428334 COMPLETED

Roflumilast in Non-CF Bronchiectasis Study

The University of Hong Kong

NCT02443688 COMPLETED

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Celtaxsys, Inc.

NCT02626182 COMPLETED

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

National Jewish Health

NCT03462056 COMPLETED

Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis

Washington University School of Medicine

NCT02354859 COMPLETED

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

University of Washington

NCT02718495 COMPLETED

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Proteostasis Therapeutics, Inc.

NCT01132482 COMPLETED

Effects of Sildenafil on CFTR-dependent Ion Transport Activity

National Jewish Health

NCT02532764 COMPLETED

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

ProQR Therapeutics

NCT03119649 COMPLETED

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Galapagos NV

NCT03154541 COMPLETED

SynRinse Irrigation Pilot (SIP) Trial

University of Washington

NCT03061331 COMPLETED

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Vertex Pharmaceuticals Incorporated

NCT02759562 TERMINATED

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Gilead Sciences

NCT03474042 COMPLETED

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Galapagos NV

NCT02453789 COMPLETED

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

AlgiPharma AS

NCT02465450 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Corbus Pharmaceuticals Inc.

NCT03045523 COMPLETED

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Galapagos NV

NCT02518672 TERMINATED

Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)

SCF Pharma

NCT02589236 COMPLETED

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

Nivalis Therapeutics, Inc.

NCT02707562 COMPLETED

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

Galapagos NV

NCT02767297 COMPLETED

Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

Flatley Discovery Lab LLC

NCT02690519 COMPLETED

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)

Galapagos NV

NCT02415959 COMPLETED

Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Abbott

NCT07437105 NOT YET RECRUITING

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

Vertex Pharmaceuticals Incorporated

NCT06154447 RECRUITING

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT06603246 RECRUITING

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

Genentech, Inc.

NCT07349394 RECRUITING

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Vertex Pharmaceuticals Incorporated

NCT07275905 NOT YET RECRUITING

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

Ghady Haidar

NCT07289464 RECRUITING

A Clinical Study of RSS0343 in Healthy Subjects

Reistone Biopharma Company Limited

NCT06995651 RECRUITING

Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

University of Pennsylvania

NCT07283770 RECRUITING

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Vertex Pharmaceuticals Incorporated

NCT07280598 NOT YET RECRUITING

Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections

University of California, San Diego

NCT07035990 RECRUITING

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Sionna Therapeutics Inc.

NCT05504837 RECRUITING

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Krystal Biotech, Inc.

NCT04624490 RECRUITING

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Mario Castro, MD, MPH

NCT05802264 RECRUITING

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

Cystetic Medicines, Inc.

NCT06299709 COMPLETED

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Vertex Pharmaceuticals Incorporated

NCT06659757 COMPLETED

A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects

Kither Biotech Srl

NCT06861413 COMPLETED

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

Vertex Pharmaceuticals Incorporated

NCT04656275 TERMINATED

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

Boehringer Ingelheim

NCT05712538 COMPLETED

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Arcturus Therapeutics, Inc.

NCT05225805 COMPLETED

Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis

Nabriva Therapeutics AG

NCT06312787 COMPLETED

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Vertex Pharmaceuticals Incorporated

NCT06299696 COMPLETED

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Vertex Pharmaceuticals Incorporated

NCT06217952 COMPLETED

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

SpliSense Ltd.

NCT04643587 COMPLETED

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

CSL Behring

NCT03104855 COMPLETED

Clearance of 25-hydroxyvitamin D in Cystic Fibrosis

University of Washington

NCT05095246 WITHDRAWN

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Krystal Biotech, Inc.

NCT05867147 COMPLETED

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Vertex Pharmaceuticals Incorporated

NCT05437120 COMPLETED

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Vertex Pharmaceuticals Incorporated

NCT02866721 COMPLETED

Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

University Hospitals Cleveland Medical Center

NCT02947126 COMPLETED

Multilevel Models of Therapeutic Response in the Lungs

Tim Corcoran

NCT05535959 COMPLETED

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Vertex Pharmaceuticals Incorporated

NCT04279769 COMPLETED

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Calithera Biosciences, Inc

NCT04926701 COMPLETED

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Enterprise Therapeutics Ltd

NCT02598999 TERMINATED

Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients

Alaxia SAS

NCT04010799 COMPLETED

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

Chiesi Farmaceutici S.p.A.

NCT03647228 COMPLETED

A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

Ionis Pharmaceuticals, Inc.

NCT04176328 COMPLETED

Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

Neupharma Srl

NCT02564354 COMPLETED

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

ProQR Therapeutics

NCT03058068 WITHDRAWN

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

Joshua M Hare

NCT03140527 COMPLETED

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Proteostasis Therapeutics, Inc.

NCT03078088 COMPLETED

Airway Alkalinization and Nasal Colonization

Lakshmi Durairaj

NCT03258424 COMPLETED

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

Proteostasis Therapeutics, Inc.

NCT02976519 COMPLETED

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

Boehringer Ingelheim

NCT03540524 COMPLETED

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

Galapagos NV

NCT02679729 COMPLETED

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

AstraZeneca

NCT03516331 COMPLETED

A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects

Flatley Discovery Lab LLC

NCT03424252 COMPLETED

An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects

Flatley Discovery Lab LLC

NCT03527095 COMPLETED

A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects

Flatley Discovery Lab LLC

NCT03173573 COMPLETED

A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

Flatley Discovery Lab LLC

NCT03589313 COMPLETED

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Galapagos NV

NCT03309358 TERMINATED

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Synspira, Inc.

NCT03093714 COMPLETED

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

Flatley Discovery Lab LLC

NCT03486236 COMPLETED

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Vertex Pharmaceuticals Incorporated

NCT03450720 COMPLETED

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Galapagos NV

NCT03056326 COMPLETED

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects

Chiesi Farmaceutici S.p.A.

NCT03029455 COMPLETED

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated

NCT03056989 COMPLETED

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Spyryx Biosciences, Inc.

NCT02468908 COMPLETED

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Savara Inc.

NCT02934139 COMPLETED

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

Nivalis Therapeutics, Inc.

NCT02275936 COMPLETED

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Nivalis Therapeutics, Inc.

NCT02605590 COMPLETED

Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers

Protalix

NCT02359357 COMPLETED

FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

Flatley Discovery Lab LLC

NCT02680418 COMPLETED

Pharmacokinetics of FDL169 in Healthy Female Subjects

Flatley Discovery Lab LLC

NCT04467957 ACTIVE NOT RECRUITING

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Children's Hospital Medical Center, Cincinnati

NCT04259970 ACTIVE NOT RECRUITING

Hyperpolarized Imaging for New Treatments

Children's Hospital Medical Center, Cincinnati

NCT05704036 RECRUITING

Estrogen Supplementation and Bone Health in Women With CF

Johns Hopkins University

NCT07148739 RECRUITING

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Arkansas Children's Hospital Research Institute

NCT06242795 RECRUITING

Hypertonic Saline in NCFB

University of North Carolina, Chapel Hill

NCT03921060 RECRUITING

Markers of Osteoporosis in Cystic Fibrosis

University of Texas Southwestern Medical Center

NCT05517655 RECRUITING

BEGIN Novel ImagiNG Biomarkers

Children's Hospital Medical Center, Cincinnati

NCT05548283 RECRUITING

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Chris Goss

NCT04602468 ACTIVE NOT RECRUITING

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

Royal College of Surgeons, Ireland

NCT05743946 COMPLETED

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Emory University

NCT05740618 COMPLETED

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

University of North Carolina, Chapel Hill

NCT04533646 COMPLETED

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Jagdeesh Ullal

NCT03771313 COMPLETED

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Children's Hospital Medical Center, Cincinnati

NCT03624101 TERMINATED

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

University of Alabama at Birmingham

NCT05276960 COMPLETED

Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF

Hospital Infantil de Mexico Federico Gomez

NCT04381429 TERMINATED

Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes

University Hospital, Strasbourg, France

NCT05561764 TERMINATED

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

Hartford Hospital

NCT05314764 COMPLETED

Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis

Hartford Hospital

NCT04210427 COMPLETED

Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

St. Louis University

NCT05069597 COMPLETED

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

AbbVie

NCT04460586 COMPLETED

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Paul Beringer

NCT04118010 COMPLETED

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

Emory University

NCT03924947 COMPLETED

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

AbbVie

NCT02918409 COMPLETED

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

National Jewish Health

NCT03632525 COMPLETED

Intravenous Iron in Adults With Cystic Fibrosis

University of Oxford

NCT03502070 COMPLETED

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Mylan Inc.

NCT02677701 COMPLETED

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

Seattle Children's Hospital

NCT02781610 COMPLETED

Standardized Treatment of Pulmonary Exacerbations II

Chris Goss

NCT02547116 WITHDRAWN

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

Johns Hopkins University

NCT02421120 COMPLETED

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Joseph L. Kuti, PharmD

NCT02444234 COMPLETED

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

University of Southern California

NCT03956589 TERMINATED

Functional Respiratory Imaging and Orkambi in CF

University Hospital, Antwerp

NCT03256968 COMPLETED

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

University of Alabama at Birmingham

NCT03172793 COMPLETED

Telavancin Pharmacokinetics in Cystic Fibrosis Patients

Joseph L. Kuti, PharmD

NCT02894684 COMPLETED

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Liverpool Heart and Chest Hospital NHS Foundation Trust

NCT03256799 COMPLETED

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

University of Alabama at Birmingham

NCT02875366 COMPLETED

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Vertex Pharmaceuticals Incorporated

NCT03724955 WITHDRAWN

Pilot E2 for Hypogonadal Women With CFBD

Emory University

NCT02504827 COMPLETED

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

University of Southern California

NCT02248922 TERMINATED

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

Novartis Pharmaceuticals

NCT02823470 TERMINATED

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Vertex Pharmaceuticals Incorporated

NCT02823964 COMPLETED

EASY: Extended Access to Sollpura Over Years

Anthera Pharmaceuticals

NCT02700282 COMPLETED

Backpack Carrying in Children With Cystic Fibrosis

Groupe Hospitalier du Havre

Data: ClinicalTrials.gov